PROGEN Share Price Performance
SEK 1.00
-22.50 (-95.74%)
Price SEK 1.00
Share PriceSEK 1.00
PROGEN Community Narratives
There are no narratives available yet.
Recent PROGEN News & Updates
No updates
Prostatype Genomics AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 12, 2026
- Earnings per share (EPS)
- -1.22
- Gross Margin
- -2,948.25%
- Net Profit Margin
- -6,336.50%
- Debt/Equity Ratio
- 0%
Prostatype Genomics AB (publ) Competitors
About PROGEN
- Founded
- 2007
- Employees
- 6
- CEO
- WebsiteView website
Prostatype Genomics AB manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.
Swedish Market Performance
- 7 Days: -2.9%
- 3 Months: 2.3%
- 1 Year: 2.0%
- Year to Date: -1.6%
Over the last 7 days, the market has dropped 2.9%, driven by pullbacks in every sector, especially the Industrials sector. Although the market performance has been flat over the past year. Looking forward, earnings are forecast to grow by 17% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading